A Mucosal Subunit Vaccine Protects against Lethal Respiratory Infection with Francisella tularensis LVS

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ashtekar, Amit R ^a,c   Katz, Jannet ^b   Xu, Qingan ^b,d   Michalek, Suzanne M ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GPI 0100; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; INTERLEUKIN 17; LIVE VACCINE; MEMBRANE PROTEIN; OUTER SURFACE PROTEIN A; PROTEIN DNAK; RECOMBINANT DNAK; RECOMBINANT PROTEIN; RECOMBINANT TUL4; TUL4 PROTEIN; TULAREMIA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FRANCISELLA TULARENSIS; IMMUNIZATION; LIVER; LUNG; LUNG LAVAGE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; RESPIRATORY TRACT INFECTION; SPLEEN; T LYMPHOCYTE; TULAREMIA;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CELLS, CULTURED; FEMALE; FRANCISELLA TULARENSIS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; MICE; RESPIRATORY TRACT INFECTIONS; TULAREMIA;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; MAMMALIA; MUS;

EID: 84870379725     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050460     Document Type: Article

References (72)

1. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285: 2763-2773.
2. Sjostedt A, (2007) Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 1105: 1-29.
3. Elkins KL, Cowley SC, Bosio CM, (2003) Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect 5: 135-142.
4. Matyas BT, Nieder HS, Telford SR, (2007) Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics. Ann N Y Acad Sci 1105: 351-377.
5. Gursky E, Inglesby TV, O'Toole T, (2003) Anthrax 2001: observations on the medical and public health response. Biosecur Bioterror 1: 97-110.
6. Forestal CA, Malik M, Catlett SV, Savitt AG, Benach JL, et al. (2007) Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis 196: 134-137.
7. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
8. Elkins KL, Cowley SC, Bosio CM, (2007) Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 1105: 284-324.
9. Sebastian S, Pinkham JT, Lynch JG, Ross RA, Reinap B, et al. (2009) Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 27: 597-605.
10. Cox JC, Coulter AR, (1997) Adjuvant-a classification and review of their modes of action. Vaccine 15: 248-256.
11. McGhee JR, Czerkinsky C, Mestecky J (1999) Mucosal vaccines; an overview. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J et al., editors. Mucosal Immunology. San Deigo: Academic Press. 741-757.
12. Newman MJ, (2000) Vaccine adjuvants. Exp Opin Ther Patents 10: 1-18.
13. Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD, (2003) Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21: 3961-3971.
14. Marciani DJ, (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8: 934-943.
15. Zhang P, Yang Q-B, Marciani DJ, Martin M, Clements JD, et al. (2003) Effectiveness of the quijalla saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine 21: 4459-4471.
16. Oyston PC, (2009) Francisella tularensis vaccines. Vaccine 27: D48-51.
17. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, et al. (2009) Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci USA 106: 4343-4348.
18. Conlan JW, Shen H, Webb A, Perry MB, (2002) Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20: 3465-3471.
19. Fulop M, Manchee R, Titball R, (1995) Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13: 1220-1225.
20. Fulop M, Mastroeni P, Green M, Titball RW, (2001) Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19: 4465-4472.
21. Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW, (2011) Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia. Vaccine 29: 6941-6947.
22. Huntley JF, Conley PG, Rasko DA, Hagman KE, Apicella MA, et al. (2008) Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 76: 3664-3671.
23. Kaur R, Chen S, Arevalo MT, Xu Q, Chen Y, et al. (2012) Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis. Clin Vaccine Immunol 19: 359-364.
24. Sjostedt A, Sandstrom G, Tarnvik A, (1992) Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect Immun 60: 2855-2862.
25. Ericsson M, Kroca M, Johansson T, Sjostedt A, Tarnvik A, (2001) Long-lasting recall response of CD4+ and CD8+ αβ T cells, but not γδ T cells, to heat shock proteins of Francisella tularensis. Scand J Infect Dis 33: 145-152.
26. Ericsson M, Tarnvik A, Kuoppa K, Sandstrom G, Sjostedt A, (1994) Increased synthesis of DnaK, GroEL, and GroES homologs by Francisella tularensis LVS in response to heat and hydrogen peroxide. Infect Immun 62: 178-183.
27. Hartley MG, Green M, Choules G, Rogers D, Rees DG, et al. (2004) Protection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide. Infect Immun 72: 4109-4113.
28. Lee B-Y, Horwitz MA, Clemens DL, (2006) Identification, recombinant expression, immunolocalization in macrophages, and T-cell responsiveness of the major extracellular proteins of Francisella tularensis. Infect Immun 74: 4002-4013.
29. Katz J, Zhang P, Martin M, Vogel SN, Michalek SM, (2006) Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun 74: 2809-2816.
30. Ashtekar AR, Zhang P, Katz J, Deivanayagam CS, Rallabhandi P, et al. (2008) TLR4-mediated activation of dendritic cells by the heat shock protein DnaK from Francisella tularensis. J Leukoc Biol 84: 1434-1446.
31. Thakran S, Li H, Lavine CL, Miller MA, Bina JE, et al. (2008) Identification of Francisella tularensis lipoproteins that stimulate the Toll-like receptor (TLR) 2/TLR1 heterodimer. J Biol Chem 283: 3751-3760.
32. Valentino MD, Hensley LL, Skrombolas D, McPherson PL, Woolard MD, et al. (2009) Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS. Mol Immunol 46: 1830-1838.
33. Woolard MD, Wilson JE, Hensley LL, Jania LA, Kawula TH, et al. (2007) Francisella tularensis-infected macrophages release prostaglandin E2 that blocks T cell proliferation and promotes a Th2-like response. J Immunol 178: 2065-2074.
34. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, et al. (2009) Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 16: 444-452.
35. Miller MA, Stabenow JM, Parvathareddy J, Wodowski AJ, Fabrizio TP, et al. (2012) Visualization of murine intranasal dosing efficiency using luminescent Francisella tularensis: effect of instillation volume and form of anesthesia. PLoS ONE 7: e31359.
36. Conlan JW, Chen W, Bosio CM, Cowley SC, Elkins KL, (2011) Infection of mice with Francisella as an immunological model. Curr Protoc Immunol 93: 19.14.1-19.14.16.
37. Cole LE, Elkins KL, Michalek SM, Qureshi N, Eaton LJ, et al. (2006) Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol 176: 6888-6899.
38. Wilson KH, Blitchington RB, Greene RC, (1990) Amplification of bacterial 16S ribosomal DNA with polymerase chain reaction. J Clin Microbiol 28: 1942-1946.
39. Cognet I, de Coignac AB, Magistrelli G, Jeannin P, Aubry JP, et al. (2003) Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J Immunol Methods 272: 199-210.
40. Forestal CA, Gil H, Monfett M, Noah CE, Platz GJ, et al. (2008) A conserved and immunodominant lipoprotein of Francisella tularensis is proinflammatory but not essential for virulence. Microb Pathog 44: 512-523.
41. Valentino MD, Maben ZJ, Hensley LL, Woolard MD, Kawula TH, et al. (2011) Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology 132: 348-360.
42. Blander SJ, Horwitz MA, (1993) Major cytoplasmic membrane protein of Legionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease. J Clin Invest 91: 717-723.
43. Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J, (2007) Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 25: 6721-6729.
44. Zugel U, Kaufmann SH, (1999) Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 12: 19-39.
45. Baron SD, Singh R, Metzger DW, (2007) Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun 75: 2152-2162.
46. Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW, (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179: 532-539.
47. Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP, (2006) Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun 74: 2063-2071.
48. Rawool DB, Bitsaktsis C, Li Y, Gosselin DR, Lin Y, et al. (2008) Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180: 5548-5557.
49. Cole LE, Mann BJ, Shirey KA, Richard K, Yang Y, et al. (2011) Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J Leukoc Biol 90: 787-797.
50. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM, (1999) Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 162: 2291-2298.
51. Pyles RB, Jezek GE, Eaves-Pyles TD, (2010) Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect Immun 78: 1700-1710.
52. Pasare C, Medzhitov R, (2005) Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 560: 11-18.
53. Cole LE, Shirey KA, Barry E, Santiago A, Rallabhandi P, et al. (2007) TLR2-mediated signaling requirements for Francisella tularensis LVS infection of murine macrophages. Infect Immun 75: 4127-4137.
54. Li H, Nookala S, Bina XR, Bina JE, Re F, (2006) Innate immune response to Francisella tularensis is mediated by TLR2 and caspase-1 activation. J Leukoc Biol 80: 766-773.
55. Malik M, Bakshi CS, Sahay B, Shah A, Lotz SA, et al. (2006) Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect Immun 74: 3657-3662.
56. Abplanalp AL, Morris IR, Parida BK, Teale JM, Berton MT, (2009) TLR-dependent control of Francisella tularensis infection and host inflammatory responses. PLoS ONE 4: e7920.
57. Green SJ, Nacy CA, Schreiber RD, Granger DL, Crawford RM, et al. (1993) Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun 61: 689-698.
58. Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA, (1992) In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun 60: 84-89.
59. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, et al. (2009) Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810.
60. Metzger DW, Bakshi CS, Kirimanjeswara GS, (2007) Mucosal immunopathogenesis of Francisella tularensis. Ann N Y Acad Sci 1105: 266-283.
61. Anthony LS, Ghadirian E, Nestel FP, Kongshavn PA, (1989) The requirement for gamma interferon in resistance of mice to experimental tularemia. Microb Pathog 7: 421-428.
62. Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK, (1996) Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun 64: 3288-3293.
63. Lindgren H, Shen H, Zingmark C, Golovliov I, Conlan W, et al. (2007) Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect Immun 75: 1303-1309.
64. Lehner T, Bergmeier LA, Wang Y, Tao L, Sing M, et al. (2000) Heat shock protein generates β-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 30: 594-603.
65. Metcalf D, (1985) The granulocyte-macrophage colony-stimulating factors. Science 229: 16-22.
66. Zhu Q-s, Ling X, Mills GB, Lowell CA, Touw IP, et al. (2006) G-CSF induced reactive oxygen species involves Lyn-PI3K-kinase-Akt and contributes to myeloid cell growth. Blood 107: 1847-1856.
67. Ojeda SS, Wang ZJ, Mares CA, Chang TA, Li Q, et al. (2008) Rapid dissemination of Francisella tularensis and the effect of route of infection. BMC Microbiol 8: 215.
68. Sharma J, Li Q, Mishra BB, Georges MJ, Teale JM, (2009) Vaccination with an attenuated strain of Francisella novicida prevents T-cell depletion and protects mice infected with the wild-type strain from severe sepsis. Infect Immun 77: 4314-4326.
69. Huntley JF, Conley PG, Hagman KE, Norgard MV, (2007) Characterization of Francisella tularensis outer membrane proteins. J Bacteriol 189: 561-574.
70. Hazlett KR, Caldon SD, McArthur DG, Cirillo KA, Kirimanjeswara GS, et al. (2008) Adaptation of Francisella tularensis to the mammalian environment is governed by cues which can be mimicked in vitro. Infect Immun 76: 4479-4488.
71. Twine SM, Mykytczuk NC, Petit MD, Shen H, Sjostedt A, et al. (2006) In vivo proteomic analysis of the intracellular bacterial pathogen, Francisella tularensis, isolated from mouse spleen. Biochem Biophys Res Commun 345: 1621-1633.
72. Dreisbach VC, Cowley S, Elkins KL, (2000) Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun 68: 1988-1996.